Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Pool Expands Remit To COVID-19

As WHO Welcomes Proposal Covering Rights To Tests, Medicines And Vaccines

Executive Summary

The Medicines Patent Pool has expanded its mandate to include treatments that will aid the global response to the coronavirus pandemic.

You may also be interested in...



Lupin Strikes Deal For Anti-TB Drug Pretomanid

Lupin and non-profit organization TB Alliance have entered into a partnership for a new therapy for highly drug-resistant tuberculosis, pretomanid, to be distributed in 140 countries and territories.

MPP And IGBA Initiatives Bolster COVID-19 Access

The Medicines Patent Pool and the International Generic and Biosimilar medicines Association have announced separate initiatives with the continued intention to facilitate access to COVID-19 treatments and vaccines, as the global threat from the novel coronavirus pandemic continues.

Coronavirus Update: GSK Stresses Need For Broad Vaccines Amid Future Pandemic Risk

Also, Neoimmune looks to interleukin therapy for mild therapy while Daiichi Sankyo bets on a mRNA vaccine.

Related Content

Topics

UsernamePublicRestriction

Register

GB149807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel